Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis in susceptible bacteria.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Treatment of serious infections caused by susceptible gram-negative bacteria,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burns,Off-label: Bacterial endocarditis prophylaxis,Off-label: Intraocular injection for endophthalmitis
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
1-2 mg/kg IV every 8 hours, adjusted based on serum concentrations and creatinine clearance.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Terminal elimination half-life: 2-3 hours in adults with normal renal function; prolonged to 24-48 hours in anuric patients requiring dose adjustment.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Gentamicin is not significantly metabolized; it is excreted primarily unchanged by glomerular filtration.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal: >90% unchanged via glomerular filtration; biliary: <2%; fecal: negligible.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
<30% bound primarily to albumin; low binding reduces displacement interactions.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
0.2-0.3 L/kg; approximates extracellular fluid volume; increased in edema, ascites, or burns.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intramuscular: ~100%; topical: minimal systemic absorption (<1%); intravenous: 100% (by definition).
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
Cr Cl 60-90 m L/min: 1.7 mg/kg every 12 hours; Cr Cl 40-59 m L/min: 1.7 mg/kg every 24 hours; Cr Cl 20-39 m L/min: 1.7 mg/kg as a single dose then adjust based on serum levels; Cr Cl <20 m L/min: 1.7 mg/kg as a single dose then redose based on serum levels; Hemodialysis: 1-2 mg/kg after dialysis with supplemental dosing based on serum levels.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No dose adjustment required for hepatic impairment; gentamicin is primarily renally eliminated.
No dosage adjustment required for hepatic impairment.
Neonates (<7 days): 4-5 mg/kg IV every 24-36 hours; Infants >7 days: 2.5 mg/kg IV every 8 hours; Children: 2-2.5 mg/kg IV every 8 hours; adjust based on serum concentrations and renal function.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Dose adjustment based on renal function; calculate Cr Cl using Cockcroft-Gault equation with ideal body weight; typical starting dose: 1-1.7 mg/kg IV every 8-12 hours, with subsequent dosing guided by serum concentrations.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
WARNING: OTOTOXICITY AND NEPHROTOXICITY. Gentamicin can cause ototoxicity (vestibular and auditory) and nephrotoxicity. Risk increases with prolonged use, high doses, renal impairment, and advanced age. Monitor renal function and auditory function regularly.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Neurotoxicity including ototoxicity and nephrotoxicity,Neuromuscular blockade leading to respiratory paralysis,Superinfection with resistant organisms,May worsen weakness in myasthenia gravis or Parkinson's disease,Use with caution in premature infants and neonates due to renal immaturity,Monitor serum drug levels to avoid toxicity
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypersensitivity to gentamicin or other aminoglycosides,Severe renal disease with anuria (relative contraindication; use only if benefits outweigh risks)
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No significant food interactions. Avoid excessive potassium intake if renal impairment.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Gentamicin is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk. First trimester: Avoid unless essential due to potential for ototoxicity and nephrotoxicity. Second and third trimesters: Use only for severe infections when alternative antibiotics are not available. Risk of fetal inner ear damage and renal impairment associated with aminoglycosides.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Gentamicin is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.15-0.2. Oral bioavailability in infants is poor, minimizing systemic absorption. However, potential for disruption of infant gut flora and direct irritation. Use with caution, especially in neonates with immature renal function. Monitor infant for diarrhea or rash.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Increased volume of distribution and enhanced renal clearance during pregnancy may necessitate higher doses or more frequent administration to achieve therapeutic serum levels. Therapeutic drug monitoring is recommended. Initial dosing based on ideal body weight and renal function; adjust to maintain target peak (6-10 mcg/m L) and trough (<2 mcg/m L) concentrations.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Monitor peak (30 min after 30-min infusion) and trough (just before next dose) levels; target peak 5-10 mcg/m L, trough <2 mcg/m L. Adjust dose in renal impairment. Avoid concurrent ototoxic/nephrotoxic drugs. Consider once-daily dosing for synergy with beta-lactams. Assess for vestibular toxicity with Romberg test.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Report any hearing loss, ringing in ears, dizziness, or balance problems immediately.,Drink plenty of fluids unless instructed otherwise by your doctor.,Inform your doctor if you have kidney disease, myasthenia gravis, or are pregnant.,This medication is given intravenously; do not mix with other drugs in the same line without pharmacy approval.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Gentamicin, an aminoglycoside antibiotic, and Amphotericin B, a polyene antifungal agent, both independently induce nephrotoxicity. Concurrent administration synergistically increases the risk of acute kidney injury, characterized by elevated serum creatinine, reduced glomerular filtration rate, and potential tubular necrosis. This additive nephrotoxic effect necessitates cautious use and enhanced monitoring."
"Pamidronic acid, a bisphosphonate, inhibits osteoclast-mediated bone resorption, reducing serum calcium levels. Gentamicin, an aminoglycoside antibiotic, can cause renal tubular injury, impairing the kidney's ability to reabsorb calcium and leading to hypocalcemia. Concurrent use increases the risk of severe, symptomatic hypocalcemia, potentially manifesting as tetany, arrhythmias, or seizures."
"Gentamicin and foscarnet both have nephrotoxic potential, and concurrent use can lead to additive or synergistic renal injury. This interaction increases the risk of acute kidney injury, particularly in patients with pre-existing renal impairment or volume depletion, and may result in reduced glomerular filtration rate and elevated serum creatinine."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis in susceptible bacteria.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 1-2 mg/kg IV every 8 hours, adjusted based on serum concentrations and creatinine clearance.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Gentamicin is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.